[1]
|
Postow, M.A., Sidlow, R. and Hellmann, M.D. (2018) Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. The New England Journal of Medicine, 378, 158-168. https://doi.org/10.1056/NEJMra1703481
|
[2]
|
Tang, S.Q., Tang, L.L., Mao, Y.P., et al. (2021) The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients. Cancer Research and Treatment, 53, 339-354. https://doi.org/10.4143/crt.2020.790
|
[3]
|
Luoma, A.M., Suo, S., Williams, H.L., et al. (2020) Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell, 182, 655-671. https://doi.org/10.1016/j.cell.2020.06.001
|
[4]
|
Suijkerbuijk, K., Kapiteijn, E. and Verheijden, R.J. (2020) Manage-ment of Immune-Related Adverse Events Affecting Outcome in Patients Treated with Checkpoint Inhibitors. JAMA On-cology, 6, 1300-1301.
https://doi.org/10.1001/jamaoncol.2020.1932
|
[5]
|
Peeraphatdit, T.B., Wang, J., Odenwald, M.A., et al. (2020) Hepatotoxicity from Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. Hepatol-ogy, 72, 315-329. https://doi.org/10.1002/hep.31227
|
[6]
|
Dubey, D., David, W.S., Reynolds, K.L., et al. (2020) Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. Annals of Neurology, 87, 659-669. https://doi.org/10.1002/ana.25708
|
[7]
|
Sears, C.R., Peikert, T., Possick, J.D., et al. (2019) Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-Related Pneumonitis. An Official American Thoracic Society Re-search Statement. American Journal of Respiratory and Critical Care Medicine, 200, E31-E43. https://doi.org/10.1164/rccm.201906-1202ST
|
[8]
|
Thuny, F., Naidoo, J. and Neilan, T.G. (2022) Cardiovascular Complications of Immune Checkpoint Inhibitors for Cancer. European Heart Journal, 43, 4458-4468. https://doi.org/10.1093/eurheartj/ehac456
|
[9]
|
Baban, B., Liu, J.Y., Qin, X., et al. (2015) Upregulation of Pro-grammed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153. PLOS ONE, 10, E124059. https://doi.org/10.1371/journal.pone.0124059
|
[10]
|
Muller, O.J., Spehlmann, M.E. and Frey, N. (2018) Car-dio-Toxicity of Checkpoint Inhibitors. Journal of Thoracic Disease, 10, S4400-S4404. https://doi.org/10.21037/jtd.2018.12.78
|
[11]
|
Pirozzi, F., Poto, R., Aran, L., et al. (2021) Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. Current Oncology Reports, 23, 13. https://doi.org/10.1007/s11912-020-01002-w
|
[12]
|
Palaskas, N., Lopez-Mattei, J., Durand, J.B., et al. (2020) Im-mune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. Journal of the American Heart Association, 9, E13757.
https://doi.org/10.1161/JAHA.119.013757
|
[13]
|
Zhang, J.C., Chen, W.D., Alvarez, J.B., et al. (2018) Cancer Im-mune Checkpoint Blockade Therapy and Its Associated Autoimmune Cardiotoxicity. Acta Pharmacologica Sinica, 39, 1693-1698. https://doi.org/10.1038/s41401-018-0062-2
|
[14]
|
Nishimura, H., Okazaki, T., Tanaka, Y., et al. (2001) Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice. Science, 291, 319-322. https://doi.org/10.1126/science.291.5502.319
|
[15]
|
Yun, S., Vincelette, N.D., Mansour, I., et al. (2015) Late Onset Ipilimumab-Induced Pericarditis and Pericardial Effusion: A Rare but Life Threatening Complication. Case Reports in Oncological Medicine, 2015, Article ID: 794842.
https://doi.org/10.1155/2015/794842
|
[16]
|
Waterhouse, P., Penninger, J.M., Timms, E., et al. (1995) Lymphopro-liferative Disorders with Early Lethality in Mice Deficient in Ctla-4. Science, 270, 985-988. https://doi.org/10.1126/science.270.5238.985
|
[17]
|
Buchbinder, E.I. and Desai, A. (2016) CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. American Journal of Clinical Oncology, 39, 98-106. https://doi.org/10.1097/COC.0000000000000239
|
[18]
|
Mahmood, S.S., Fradley, M.G., Cohen, J.V., et al. (2018) Myocarditis in Patients Treated with Immune Checkpoint Inhibitors. Journal of the American College of Cardiol-ogy, 71, 1755-1764. https://doi.org/10.1016/j.jacc.2018.02.037
|
[19]
|
Mocan-Hognogi, D.L., Tranca, S., Farcas, A.D., et al. (2021) Immune Checkpoint Inhibitors and the Heart. Frontiers in Cardiovascular Medicine, 8, Article ID: 726426. https://doi.org/10.3389/fcvm.2021.726426
|
[20]
|
Patel, R.P., Parikh, R., Gunturu, K.S., et al. (2021) Cardi-otoxicity of Immune Checkpoint Inhibitors. Current Oncology Reports, 23, Article No. 79. https://doi.org/10.1007/s11912-021-01070-6
|
[21]
|
Esfahani, K., Buhlaiga, N., Thebault, P., et al. (2019) Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy. The New England Journal of Medicine, 380, 2375-2376. https://doi.org/10.1056/NEJMc1903064
|
[22]
|
Ala, C.K., Klein, A.L. and Moslehi, J.J. (2019) Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management. Current Cardiology Reports, 21, Article No. 156.
https://doi.org/10.1007/s11886-019-1225-6
|
[23]
|
Chen, D.Y., Huang, W.K., Chien-Chia, W.V., et al. (2020) Car-diovascular Toxicity of Immune Checkpoint Inhibitors in Cancer Patients: A Review When Cardiology Meets Immu-no-Oncology. Journal of the Formosan Medical Association, 119, 1461-1475. https://doi.org/10.1016/j.jfma.2019.07.025
|
[24]
|
Saade, A., Mansuet-Lupo, A., Arrondeau, J., et al. (2019) Pericar-dial Effusion under Nivolumab: Case-Reports and Review of the Literature. The Journal for ImmunoTherapy of Cancer, 7, Article No. 266.
https://doi.org/10.1186/s40425-019-0760-4
|
[25]
|
Poels, K., Van Leent, M., Boutros, C., et al. (2020) Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in Atherosclerosis. JACC: CardioOncolo-gy, 2, 599-610.
https://doi.org/10.1016/j.jaccao.2020.08.007
|
[26]
|
Saigusa, R., Winkels, H. and Ley, K. (2020) T Cell Subsets and Functions in Atherosclerosis. Nature Reviews Cardiology, 17, 387-401. https://doi.org/10.1038/s41569-020-0352-5
|
[27]
|
Spallarossa, P., Meliota, G., Brunelli, C., et al. (2018) Potential Cardiac Risk of Immune-Checkpoint Blockade as Anticancer Treatment: What We Know, What We Do Not Know, and What We Can Do to Prevent Adverse Effects. Medicinal Research Reviews, 38, 1447-1468. https://doi.org/10.1002/med.21478
|
[28]
|
Baraibar, I., Melero, I., Ponz-Sarvise, M., et al. (2019) Safety and Tolera-bility of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. Drug Safety, 42, 281-294. https://doi.org/10.1007/s40264-018-0774-8
|
[29]
|
Escudier, M., Cautela, J., Malissen, N., et al. (2017) Clinical Fea-tures, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. Circulation, 136, 2085-2087.
https://doi.org/10.1161/CIRCULATIONAHA.117.030571
|
[30]
|
Ronen, D., Bsoul, A., Lotem, M., et al. (2022) Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. Vaccines (Basel), 10, 540. https://doi.org/10.3390/vaccines10040540
|
[31]
|
Heinzerling, L., Ott, P.A., Hodi, F.S., et al. (2016) Cardiotoxicity Associated with CTLA4 and PD1 Blocking Immunotherapy. The Journal for ImmunoTherapy of Cancer, 4, Article No. 50. https://doi.org/10.1186/s40425-016-0152-y
|
[32]
|
Zimmer, L., Goldinger, S.M., Hofmann, L., et al. (2016) Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy. European Journal of Cancer, 60, 210-225.
https://doi.org/10.1016/j.ejca.2016.02.024
|
[33]
|
Guo, X., Wang, H., Zhou, J., et al. (2020) Clinical Manifestation and Management of Immune Checkpoint Inhibitor-Associated Cardiotoxicity. Thoracic Cancer, 11, 475-480. https://doi.org/10.1111/1759-7714.13250
|
[34]
|
Ederhy, S., Cautela, J., Ancedy, Y., et al. (2018) Takotsubo-Like Syndrome in Cancer Patients Treated with Immune Checkpoint Inhibitors. JACC: Cardiovascular Imaging, 11, 1187-1190. https://doi.org/10.1016/j.jcmg.2017.11.036
|
[35]
|
Geisler, B.P., Raad, R.A., Esaian, D., et al. (2015) Apical Ballooning and Cardiomyopathy in a Melanoma Patient Treated with Ipilimumab: A Case of Takotsubo-Like Syndrome. The Journal for ImmunoTherapy of Cancer, 3, Article No. 4. https://doi.org/10.1186/s40425-015-0048-2
|
[36]
|
Slawinski, G., Wrona, A., Dabrowska-Kugacka, A., et al. (2020) Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review. Interna-tional Journal of Molecular Sciences, 21, 7195.
https://doi.org/10.3390/ijms21197195
|
[37]
|
Bonaca, M.P., Olenchock, B.A., Salem, J.E., et al. (2019) Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation, 140, 80-91.
https://doi.org/10.1161/CIRCULATIONAHA.118.034497
|
[38]
|
Tomita, Y., Sueta, D., Kakiuchi, Y., et al. (2017) Acute Coronary Syndrome as a Possible Immune-Related Adverse Event in a Lung Cancer Patient Achieving a Complete Response to Anti-PD-1 Immune Checkpoint Antibody. Annals of Oncology, 28, 2893-2895. https://doi.org/10.1093/annonc/mdx326
|
[39]
|
Martin, H.R., Saavedra, S.C., Perna, C., et al. (2019) Cardiac Toxicity of Immune-Checkpoint Inhibitors: A Clinical Case of Nivolumab-Induced Myocarditis and Review of the Evidence and New Challenges. Cancer Management and Research, 11, 4541-4548. https://doi.org/10.2147/CMAR.S185202
|
[40]
|
Berg, D.D., Vaduganathan, M., Nohria, A., et al. (2017) Im-mune-Related Fulminant Myocarditis in a Patient Receiving Ipilimumab Therapy for Relapsed Chronic Myelomonocyt-icleukaemia. European Journal of Heart Failure, 19, 682-685. https://doi.org/10.1002/ejhf.806
|
[41]
|
Awadalla, M., Mahmood, S.S., Groarke, J.D., et al. (2020) Global Longitudinal Strain and Cardiac Events in Patients with Immune Checkpoint Inhibitor-Related Myocarditis. Journal of the American College of Cardiology, 75, 467-478.
https://doi.org/10.1016/j.jacc.2019.11.049
|
[42]
|
Laubli, H., Balmelli, C., Bossard, M., et al. (2015) Acute Heart Failure Due to Autoimmune Myocarditis under Pembrolizumab Treatment for Metastatic Melanoma. The Journal for ImmunoTherapy of Cancer, 3, Article No. 11.
https://doi.org/10.1186/s40425-015-0057-1
|
[43]
|
Khunger, A., Battel, L., Wadhawan, A., et al. (2020) New In-sights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity. Current Oncology Reports, 22, Article No. 65.
https://doi.org/10.1007/s11912-020-00925-8
|
[44]
|
Ganatra, S. and Neilan, T.G. (2018) Immune Checkpoint Inhibi-tor-Associated Myocarditis. Oncologist, 23, 879-886.
https://doi.org/10.1634/theoncologist.2018-0130
|
[45]
|
Celutkiene, J., Pudil, R., Lopez-Fernandez, T., et al. (2020) Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Car-dio-Oncology Council of the European Society of Cardiology (ESC). European Journal of Heart Failure, 22, 1504-1524. https://doi.org/10.1002/ejhf.1957
|